Microbot Medical (Nasdaq:MBOT) announced today that it entered into definitive agreements for the purchase and sale of common stock for proceeds of $7 million. The offering includes just over 4 million shares of common stock priced at $1.75 per share. In an additional concurrent private placement, the company plans to issue unregistered … [Read more...] about Microbot Medical announces $7M offering to support surgical robot commercialization
Microbot Medical
Microbot Medical submits Liberty surgical robot to FDA
Microbot Medical (Nasdaq:MBOT) announced today that it submitted an FDA 510(k) premarket notification for its Liberty surgical robot. Microbot designed its Liberty single-use endovascular surgical robot for potential use in neurovascular, cardiovascular and peripheral vascular procedures. The system includes a compact design and remote operating … [Read more...] about Microbot Medical submits Liberty surgical robot to FDA
Microbot Medical expands U.S. operations to prep for first in-human clinical study
Microbot Medical, the developer of the Liberty endovascular robotic surgical system, is building on the momentum from the positive results of its good laboratory practices (GLP) pre-clinical study. The company is adding a clinical research associate to support its pending investigational device exemption, or IDE, submission to commence its … [Read more...] about Microbot Medical expands U.S. operations to prep for first in-human clinical study
Microbot Medical is a step closer to an FDA IDE submission
Microbot Medical today announced the successful completion of its pivotal pre-clinical study of its Liberty endovascular robotic surgical system. The study, performed under good laboratory practice (GLP) and essential for the company's investigational device exemption (IDE) submission, took place under rigorous FDA guidelines. The study involved … [Read more...] about Microbot Medical is a step closer to an FDA IDE submission
